K. Omote et al., POTENTIATION OF ANTINOCICEPTIVE EFFECTS OF MORPHINE BY CALCIUM-CHANNEL BLOCKERS AT THE LEVEL OF THE SPINAL-CORD, Anesthesiology, 79(4), 1993, pp. 746-752
Background: opioids inhibit voltage-dependent calcium-channel conducta
nce, which is essential for the nervous system to be able to signal a
painful event. Accordingly, interference with calcium-channel conducta
nce may enhance opioid analgesia. The current study was designed to in
vestigate the effects of calcium-channel blocking drugs on the antinoc
iception of morphine at the level of the spinal cord. Methods: Rats we
re chronically implanted with catheters in the lumbar intrathecal spac
e. Tail-flick test was used to assess thermal nociception. Intrathecal
ly administered drugs were morphine, calcium-channel blockers (verapam
il, diltiazem, and nicardipine), or a combination of morphine and calc
ium-channel blocker. Results: Intrathecal administration of morphine p
roduced a significant dose-dependent antinociception in the tail-flick
test. In contrast, intrathecal administration of calcium-channel bloc
kers, verapamil, diltiazem. and nicardipine, did not show any antinoci
ception at the employed doses. However, when intrathecally administere
d calcium-channel blockers, verapamil (50 mug), diltiazem (100 mug), o
r nicardipine (20 mug), were combined with ineffective (0.25. 0.5, 1,
or 2 mug) or moderately effective (5 mug) doses of intrathecally admin
istered morphine, significant antinociception was produced. These inte
ractions were synergistic. There were no significant changes in MAP or
HR after the intrathecal administration of 200 mug verapamil or 2 mug
morphine combined with 50 mug verapamil. Conclusions: The authors int
erpreted these results to indicate that calcium-channel blocking drugs
synergistically potentiate the analgesic effects of morphine at the l
evel of the spinal cord. Before these results can be translated into c
linical use, however, adequate toxicity studies must be conducted to e
xamine the effect of the perispinal administration of calcium-channel
blocking drugs on spinal cord function.